MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin

Cancer Cell International

Volumn 16, Issue 1, 2016, Pages

  Li, Weili ^a   Wang, Wenzhe ^a   Ding, Mingjian ^a   Zheng, Xiaoliang ^a   Ma, Shenglin ^a,b   Wang, Xiaoju ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

Cisplatin resistance; MicroRNA; Non small cell lung cancer; Target therapy

Indexed keywords

CISPLATIN; MICRORNA; MICRORNA 1244; MICRORNA 182; MICRORNA 224; MICRORNA 589; PROTEIN P53; UBIQUITIN PROTEIN LIGASE NEDD4; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL LINE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIZATION; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84962910477     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/s12935-016-0305-6     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584-94.
3. Judson I, Kelland LR. New developments and approaches in the platinum arena. Drugs. 2000;59(Suppl 4):29-36 (discussion 37-28).
4. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol. 1999;11(1):68-75.
5. Rosell R, Lord RV, Taron M, Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer. 2002;38(3):217-27.
6. Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012;64(3):706-21.
7. Hornstein E, Mansfield JH, Yekta S, Hu JK, Harfe BD, McManus MT, Baskerville S, Bartel DP, Tabin CJ. The microRNA miR-196 acts upstream of Hoxb8 and Shh in limb development. Nature. 2005;438(7068):671-4.
8. Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350-5.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-97.
10. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215-33.
11. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009;136(4):642-55.
12. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005;33(4):1290-7.
13. Xu P, Guo M, Hay BA. MicroRNAs and the regulation of cell death. Trends Genet TIG. 2004;20(12):617-24.
14. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11(9):597-610.
15. Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, Kornmann M, Ju J. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer. 2010;9:96.
16. Macfarlane LA, Murphy PR. MicroRNA: biogenesis, function and role in cancer. Curr Genomics. 2010;11(7):537-61.
17. Xiang Q, Tang H, Yu J, Yin J, Yang X, Lei X. MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2. Pharmazie. 2013;68(4):274-81.
18. Bian HB, Pan X, Yang JS, Wang ZX, De W. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res. 2011;30:20.
19. Yan DM, Zheng XL, Tu LL, Jia J, Li Q, Chen LY, Wang XJ. Knockdown of Merm1/Wbscr22 attenuates sensitivity of H460 non-small cell lung cancer cells to SN-38 and 5-FU without alteration to p53 expression levels. Mol Med Reports. 2015;11:295-302.
20. Xu C, Fan CD, Wang X. Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase. Oncogene. 2015;34(3):281-9.
21. Wu X, Xiao H. miRNAs modulate the drug response of tumor cells. Sci China C Life Sci Chin Acad Sci. 2009;52(9):797-801.
22. Haenisch S, Cascorbi I. miRNAs as mediators of drug resistance. Epigenomics. 2012;4(4):369-81.
23. Zhang K, Zhang H, Zhou X, Tang WB, Xiao L, Liu YH, Liu H, Peng YM, Sun L, Liu FY. miRNA589 regulates epithelial-mesenchymal transition in human peritoneal mesothelial cells. J Biomed Biotechnol. 2012;2012:673096.
24. Song L, Li Y, Li W, Wu S, Li Z. miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A). J Cell Biochem. 2014;115(7):1234-42.
25. Zhang R, Zhang Y, Li H. miR-1244/myocyte enhancer factor 2D regulatory loop contributes to the growth of lung carcinoma. DNA Cell Biol. 2015;34(11):692-700.
26. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N, Haley JD. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005;65(20):9455-62.